Search Result

Results for "

FAPs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Payload (3) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Bacterial (1) Biochemical Assay Reagents (2) Dipeptidyl Peptidase (3) Drug Derivative (1) Drug Intermediate (5) Drug-Linker Conjugates for ADC (1) ERK (1) FAP (77) Fluorescent Dye (2) GLUT (1) Histone Methyltransferase (1) HIV (1) Interleukin Related (1) Microtubule/Tubulin (2) PI3K (1) Prolyl Endopeptidase (PREP) (6) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (10) Reference Standards (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (87) Infection (1) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

102

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13233A

Talabostat mesylate Maximum Cited Publications 42 Publications Verification Val-boroPro mesylate; PT100 mesylate	Dipeptidyl Peptidase	Inflammation/Immunology Cancer
Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC₅₀ < 4 nM; K_i = 0.18 nM) and the inhibitor of fibroblast activation protein *(FAP)* (IC₅₀ = 560 nM), inhibits DPP8/9 (IC₅₀ = 4/11 nM; K_i = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC₅₀ = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .

HY-128643

FAPI-4 30+ Cited Publications	FAP	Cancer
FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. ⁶⁸Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .

HY-147057

Rofapitide tetraxetan 5+ Cited Publications FAP-2286	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to *FAP*. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .

HY-137331

FAPI-46 2 Publications Verification	FAP	Cancer
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with ⁶⁸Ga or ¹⁷⁷Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .

HY-100684

UAMC-1110 2 Publications Verification	Prolyl Endopeptidase (PREP) FAP	Cancer
UAMC-1110 is a highly potent and selective inhibitor of fibroblast activation protein (FAP) with an IC₅₀ of 3.2 nM. UAMC-1110 also inhibits prolyl oligopeptidase (PREP) with an IC₅₀ of 1.8 μM .

HY-101801

Ac-Gly-BoroPro 5 Publications Verification	FAP	Cancer
Ac-Gly-BoroPro is a selective *FAP* inhibitor with a K_i of 23 nM.

HY-P99269

Sibrotuzumab 1 Publications Verification BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-47979

FAP-IN-2 1 Publications Verification	FAP	Cancer
FAP-IN-2 is an isonitrile-containing fibroblast activation protein (FAP) inhibitor. FAP-IN-2 can be labeled with technetium-99m ( ^99mTc) for targeted tumor SPECT imaging .

HY-147173

FAPI-74	FAP	Cancer
FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP). FAPI-74 can be used for FAP-positive tumor research .

HY-13233

Talabostat Val-boroPro; PT100	Dipeptidyl Peptidase	Inflammation/Immunology Cancer
Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC₅₀ < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein *(FAP)* (IC₅₀ = 560 nM), inhibits DPP8/9 (IC₅₀ = 4/11 nM; K_i = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC₅₀ = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .

HY-164316

FT-FAPI-12_9	FAP	Others
FT-FAPI-12_9 is a FAP ligand that can be used to synthesize FAPI-46, a radiotracer targeting *FAP* .

HY-172317

AZD2389	FAP	Metabolic Disease
AZD2389 is a potent and orally active *FAP* inhibitor. AZD2389 can be used for the study of metabolic dysfunction-associated steatohepatitis .

HY-P10944

Unlabeled FXX489 NNS309	FAP	Inflammation/Immunology Cancer
Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .

HY-136641

NOTA-FAPI	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality .

HY-145938

OncoFAP	FAP	Cancer
OncoFAP is an ultra-high-affinity ligand of fibroblast activation protein (FAP) for targeting applications with pan-tumoral potential.

HY-145983

Suc-Gly-Pro-AMC 1 Publications Verification	FAP Prolyl Endopeptidase (PREP)	Cancer
Suc-Gly-Pro-AMC is a fluorescent substrate. Suc-Gly-Pro-AMC is a fibroblast activation protein (FAP) specific substrate. Suc-Gly-Pro-AMC reacts with recombinant porcine prolyl oligopeptidase. Suc-Gly-Pro-AMC can be used to study the activity of FAP, prolyl endopeptidase (PREP). Suc-Gly-Pro-AMC is used in glioma research .

HY-P10945

FAP targeting peptide for FXX489	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .

HY-153552A

NH2-UAMC1110 TFA	FAP	Cancer
NH2-UAMC1110 TFA is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 TFA is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose effect, and has been used in tumor diagnosis. NH2-UAMC1110 TFA structurally incorporates an active amino group, allowing it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.) to synthesize molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 TFA specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling-related processes. Its key activity is high targeting and high affinity, and its core function is to act as a targeting module coupled with bifunctional chelators (such as DOTA, DATA5m). NH2-UAMC1110 TFA can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .

HY-P990245

*Anti-Mouse FAP* Antibody (73.3)**	FAP	Cancer
Anti-Mouse FAP Antibody (73.3) is an anti-mouse *FAP* IgG1 monoclonal antibody. Anti-Mouse FAP Antibody (73.3) can be used to accurately detect the expression and localization of FAP protein in mice. Anti-Mouse FAP Antibody (73.3) can be used for research on cancer .

HY-139401

FAPI-34	FAP	Cancer
FAPI-34 is a SPECT imaging agent targeting *FAP. FAPI-34 specifically binds to FAP, is highly internalized by FAP*-expressing cells, accumulates in *FAP*-expressing tumor lesions, and shows low uptake in normal tissues except the kidneys. FAPI-34 is applicable for tumor-related research .

HY-148127

TAM558	Drug-Linker Conjugates for ADC	Cancer
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective *FAP* inhibitor with an IC₅₀ value of 0.9 nM against *FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP*-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-153552

NH2-UAMC1110	FAP	Cancer
NH2-UAMC1110 is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose-response, and has been used for tumor diagnosis. NH2-UAMC1110 introduces an active amino group into its structure, enabling it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.), thereby synthesizing molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling processes. Its key activity is high targeting and high affinity, and its core function is to be coupled with bifunctional chelators (such as DOTA, DATA5m) as a targeting module. NH2-UAMC1110 can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .

HY-P99902

Simlukafusp alfa FAP-IL2v; RO6874281; RG7461	Interleukin Related	Cancer
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .

HY-160289

ARI-3144	FAP	Cancer
ARI-3144 is an excellent and specific substrate for fibroblast activation protein (FAP). ARI-3144 is usually coupled with the fluorophore 7-Amino-4-methylcoumarin (HY-D0027) (AMC) for detection and quantification of FAP .

HY-125366

ARI-3099	FAP	Metabolic Disease
ARI-3099 is an oral fibroblast activation protein (FAP) inhibitor. ARI-3099 specifically inhibits the proteolytic activity of *FAP* and blocks the cleavage of human FGF-21 between residues P171 and S172. ARI-3099 extends the half-life of circulating human FGF-21 in mice. ARI-3099 can be used in the research of type 2 diabetes and metabolic disorders .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of *FAP* that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-173374

*DOTAGA-FAP-2286-ALB*	FAP Drug Derivative	Cancer
DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC₅₀ value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .

HY-W404002

BR102910	Prolyl Endopeptidase (PREP)	Metabolic Disease
BR102910 is a selective fibroblast activation protein (FAP) inhibitor with the IC₅₀ of 2 nM. BR102910 also inhibits prolyl oligopeptidase (PREP) with the IC₅₀ of 49.00 μM. BR102910 can be used for the researchof type 2

HY-154844

FAP Ligand 1	Biochemical Assay Reagents	Cancer
FAP Ligand 1 (FL), a high-affinity FAP small-molecule ligand, is used to target attached drugs to FAP-expressing fibroblasts and can be used in radiation imaging studies of targeted cancers .

HY-161074

PNT6555	FAP	Cancer
PNT6555 is a fibroblast activation protein-α (FAP) inhibitor. PNT6555 has antitumor activity. PNT6555 can be used for imaging of *FAP*-positive tumors .

HY-159768A

DOTAGA.Glu.(FAPi)2	Radionuclide-Drug Conjugates (RDCs) FAP	Neurological Disease Cancer
DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium- ⁶⁸, lutetium- ¹⁷⁷ or terbium- ¹⁶¹, DOTAGA.Glu.(FAPi) 2 is applicable to *FAP*-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme .

HY-175350

OncoFAP-GlyPro-MMAE OncoFAP glidotin	FAP Microtubule/Tubulin	Cancer
OncoFAP-GlyPro-MMAE is a *FAP* small molecule-drug conjugate (SMDC) with an IC₅₀ of 0.49  nM. OncoFAP-GlyPro-MMAE consists of a FAP Ligand OncoFAP (HY-145938), a Tubulin inhibitor (MMAE) (HY-15162) and a linker. OncoFAP-GlyPro-MMAE can be used for cancers like renal cancer research .

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research .

HY-177435

FAPI-800CW	FAP	Inflammation/Immunology
FAPI-800CW is a near-infrared (NIR) fluorescent-labeled fibroblast activation protein (FAP) inhibitor. FAPI-800CW shows specific uptake in inflamed paws in collagen-induced arthritis (CIA) model mice. FAPI-800CW can be used for in vivo molecular imaging of *FAP* expression in inflammatory diseases such as rheumatoid arthritis (RA) to monitor joint inflammation and disease activity .

HY-175613

DOTA-ALB-02	FAP	Cancer
DOTA-ALB-02 is an albumin-bound *FAP* inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with ¹⁷⁷Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .

HY-148128

TAM470	Microtubule/Tubulin ADC Payload	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-177459

DOTA-2P(FAPI)2	FAP	Cancer
DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy .

HY-177083

Faridoxorubicin AVA-6000	FAP	Cancer
Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis) .

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research .

HY-176958

OncoFAP-EN-DOTAGA	FAP	Others
OncoFAP-EN-DOTAGA is a *FAP* (fibroblast activation protein) targeting conjugate compound. OncoFAP-EN-DOTAGA can chelate radioactive isotopes (such as ) Ga-68 or fluorescent agent and can be used as a probe with targeting binding functions .

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-D2281

FAP Ligand 2	FAP	Cancer
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-147057A

Rofapitide tetraxetan acetate FAP-2286 acetate	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to *FAP*. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .

HY-175353

TriOncoFAP-GlyPro-MMAE	FAP	Cancer
TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC₅₀ of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE) .

HY-175685

FAP-IN-7	FAP	Cancer
FAP-IN-7 (Compound 5b) is a FAPFAP-IN-7 labeled with 18F enhances tumor retention with high selectivity and favorable pharmacokinetics. FAP-IN-7 can be used as a radiotracer for PET imaging and radionuclide therapy of cancers research .

HY-175322

FAPI-P8PN	FAP	Cancer
FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC₅₀=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors .

HY-145358

FAP-PI3KI1	PI3K	Cancer
FAP-PI3KI1 is a fibroblast-activated protein (FAP)-targeted PI3K inhibitor that selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells and effectively inhibits collagen synthesis and reduces collagen deposition .

HY-174421

FAPI-JNU	FAP	Cancer
FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [ ⁶⁸Ga]Ga or [ ¹⁷⁷Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors) .

Cat. No.	Product Name	Type

HY-W010991

N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly

1 Publications Verification

FAPGG

Fluorescent Dye

N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly (FAPGG) is a specific substrate of angiotensin converting enzyme (ACE) with a Ki of 2.546×10 ^-4 M. It is used as a chromogenic probe for quantitative detection of ACE activity. N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly can be hydrolyzed by ACE to generate N-[3-(2-furyl)acryloyl]-Phe (FAP) and Gly-Gly, and the ACE inhibitory effect is monitored by photometry. FAPGG competitively binds to the active center of ACE and is a key tool for screening ACE inhibitors such as Captopril (HY-B0368) and Dioscorin. Its reversible mechanism of action supports hypertension research and drug development targeting the renin-angiotensin system .

HY-D2281

FAP Ligand 2	Fluorescent Dye
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-D3192

CDy11

Fluorescent Dye

CDy11 is a fluorescent probe and amyloid-binding dye (λ_ex=590 nm; λ_em=612 nm), with a K_a of 29 μM for Pseudomonas aeruginosa Fap. CDy11 specifically recognizes amyloid fibrils in bacterial biofilms and exhibits significantly enhanced fluorescence upon binding to the target. CDy11 shows no staining effect on amyloid-deficient mutant strains, planktonic cells or protein monomers. CDy11 supports in vivo imaging of Pseudomonas aeruginosa biofilms in mouse implant and corneal infection models. CDy11 is widely used in studies of Staphylococcus aureus biofilm infections, dental caries, and Pseudomonas aeruginosa-associated implant and corneal infections .

Cat. No.	Product Name	Target	Research Area

HY-W010991

N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly 1 Publications Verification FAPGG	Angiotensin-converting Enzyme (ACE)	Others
N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly (FAPGG) is a specific substrate of angiotensin converting enzyme (ACE) with a Ki of 2.546×10 ^-4 M. It is used as a chromogenic probe for quantitative detection of ACE activity. N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly can be hydrolyzed by ACE to generate N-[3-(2-furyl)acryloyl]-Phe (FAP) and Gly-Gly, and the ACE inhibitory effect is monitored by photometry. FAPGG competitively binds to the active center of ACE and is a key tool for screening ACE inhibitors such as Captopril (HY-B0368) and Dioscorin. Its reversible mechanism of action supports hypertension research and drug development targeting the renin-angiotensin system .

HY-P10944

Unlabeled FXX489 NNS309	FAP	Inflammation/Immunology Cancer
Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .

HY-P10945

FAP targeting peptide for FXX489	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective *FAP* inhibitor with an IC₅₀ value of 0.9 nM against *FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP*-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent and selective peptide inhibitor of *FAP* that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .

HY-P3441A

3BP-4089 TFA	FAP	Cancer
3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research .

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3441

3BP-4089	FAP	Cancer
3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research .

HY-159771

FAP6-19	FAP	Cancer
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a K_d of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.

HY-P10945B

*Cys-FAP* targeting peptide for FXX489 TFA**	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
Cys-FAP targeting peptide for FXX489 TFA is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .

HY-P10946

FAP targeting peptide-PEG2 conjugate	Radionuclide-Drug Conjugates (RDCs)	Cancer
FAP targeting peptide-PEG2 conjugate (Example A1) is the peptide (HY-P10945) and linker conjugate of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .

HY-P11254

DOTA-FAPT	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-FAPT is a novel targeting *FAP* tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .

HY-P4448

Ac-Gly-Pro-AFC	Fluorescent Dye	Others
Ac-Gly-Pro-AFC is a fluorogenic substrate for the determination of fibroblast activation protein (FAP) endopeptidase activity .

HY-P11602

*DOTA-C1-FAP-2286*	FAP	Cancer
DOTA-C1-FAP-2286 is a cysteic acid-modified fibroblast activation protein (FAP)-targeting radioligand. DOTA-C1-FAP-2286 binds competitively to FAP with an IC₅₀ of 127.64 nM. DOTA-C1-FAP-2286 is targeted accumulation in FAP-expressing cells and exhibits accelerated renal clearance. DOTA-C1-FAP-2286 can be used as a PET/CT tracer in cancer .

HY-P10945A

*Cys-FAP* targeting peptide for FXX489**	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
Cys-FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .

HY-P11599

NOTA-SP2A-FAPT	FAP	Cancer
NOTA-SP2A-FAPT is a fibroblast activation protein (FAP) ligand. NOTA-SP2A-FAPT can be adiolabeled and exhibits rapid renal excretion with fast kidney tissue clearance, accumulates rapidly in and retains high levels in FAP-positive tumor xenografts to enable clear tumor visualization. NOTA-SP2A-FAPT can be used as a tracer of cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99269

Sibrotuzumab 1 Publications Verification BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-P990245

*Anti-Mouse FAP* Antibody (73.3)**	FAP	Cancer
Anti-Mouse FAP Antibody (73.3) is an anti-mouse *FAP* IgG1 monoclonal antibody. Anti-Mouse FAP Antibody (73.3) can be used to accurately detect the expression and localization of FAP protein in mice. Anti-Mouse FAP Antibody (73.3) can be used for research on cancer .

HY-P99902

Simlukafusp alfa FAP-IL2v; RO6874281; RG7461	Interleukin Related	Cancer
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .

HY-P991995

OMTX005 OMTX705 antibody	ADC Antibody FAP	Cancer
OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC₅₀: 0.33 nM)/mouse (EC₅₀: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: